研發新進展：對抗HIV的新抗體有新的突破

<p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋體">近期，上海酶聯生物報導：對立</font>HIV<font face="宋體">的新抗體有望打破！</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><strong><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;">ELISA<font face="宋體">試劑盒</font></span></strong><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋體">研討人員標明，能發生很多中和抗體（</font><font face="Calibri">bNAbs</font><font face="宋體">）的艾滋病</font><font face="Calibri">HIV</font><font face="宋體">攜帶者比那些不能發生此類抗體的人，有不同的免疫活化系統。中和抗體是一種有助于按捺艾滋病</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;">b<font face="宋體">毒</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋體">的抗體，但是</font>bNAbs <font face="宋體">不能徹底的清除艾滋病患者體內的</font><font face="Calibri">HIV</font><font face="宋體">傳染源，但科學家以為一個成功的防備</font><font face="Calibri">HIV</font><font face="宋體">的疫苗有必要能誘導</font><font face="Calibri">bNAbs</font><font face="宋體">。</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋體">新的研討標明，</font>bNAbs<font face="宋體">的生成可能與特定個別免疫功用的改變有關，這種免疫功用可能不是受</font><font face="Calibri">HIV</font><font face="宋體">感染而發生。</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋體">界說怎么安全的仿制這些不是經</font>HIV<font face="宋體">感染而發生的疫苗受體，能更好的指導規劃實驗取得防備艾滋病的疫苗。這項研討由國家過敏癥和流行癥研討所（</font><font face="Calibri">NIAID</font><font face="宋體">）資助支撐，</font><font face="Calibri">NIAID</font><font face="宋體">是美國國立衛生研討院的一部分。</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋體">杜克大學的研討人員領導的一個團隊，經過搜集</font>HIV<font face="宋體">攜帶者的血樣并加以研討，發現出了這種免疫改變。該團隊將</font><font face="Calibri">51</font><font face="宋體">個含很多</font><font face="Calibri">bNAbs</font><font face="宋體">個別的血樣同</font><font face="Calibri">51</font><font face="宋體">個不含或含很少</font><font face="Calibri">bNAbs</font><font face="宋體">的個別血樣作了比較，分析結果標明，許多由慢性</font><font face="Calibri">HIV</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;">b<font face="宋體">毒</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋體">感染引發的免疫細胞功用的改變與高水平的</font>bNAbs<font face="宋體">相關聯。</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋體">免疫功用的特定改變包含：高頻率的攻擊本身細胞的抗體</font>&mdash;&mdash;本身抗體、少量免疫調理性<font face="Calibri">T</font><font face="宋體">細胞&mdash;&mdash;在這些個別中也很少被激活、高頻率的回憶</font><font face="Calibri">T</font><font face="宋體">卵泡輔佐細胞。</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋體">在這種免疫系統結構下，能發生抗體的免疫細胞</font>&mdash;&mdash;<font face="Calibri">B</font><font face="宋體">細胞的活性可能不受按捺，由于該免疫系統支撐</font><font face="Calibri">T</font><font face="宋體">卵泡輔佐細胞，也可能被調理性</font><font face="Calibri">T</font><font face="宋體">細胞阻止。反之，這可能導致</font><font face="Calibri">bNAbs</font><font face="宋體">更有用的生成來對立</font><font face="Calibri">HIV</font><font face="宋體">。這些發現為研發能改善個別免疫系統的</font><font face="Calibri">HIV</font><font face="宋體">疫苗供給了一個捷徑。</font></span><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋體;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;">重視上海酶聯生物科技，我司為您供給后續動態，關于抗體產品，我司供給技術支撐。歡迎來電咨詢。</span><span style="mso-spacerun:'yes';font-family:Calibri;mso-fareast-font-family:宋體;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p>